Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

1

US Approved Rx

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Androgen Receptor

1

Glucocorticoid receptor

1

Mineralocorticoid receptor

1

Progesterone receptor

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1960

1

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Congestive heart failure

1

Discrete aldosterone-producing adrenal adenomas

1

Essential hypertension

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Searle

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

ECHA (EC/EINECS)

2

EPA CompTox

2

FDA UNII

2

HSDB

2

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

CARDIOVASCULAR SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

DIURETICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

POTASSIUM-SPARING AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Aldosterone antagonists

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

2

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

SPIRONOLACTONE

27O7W4T232

Export Data
Search for Structure

Status:

US Approved Rx (2016)

First approved in 1960

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Mineralocorticoid receptor

Androgen Receptor

Progesterone receptor

Glucocorticoid receptor

Conditions:

Essential hypertension

Discrete aldosterone-producing adrenal adenomas

Congestive heart failure

Spironolactone is a synthetic 17-lactone steroid which is a renal competitive aldosterone antagonist in a class of pharmaceuticals called potassium-sparing diuretics. On its own, spironolactone is only a weak diuretic, but it can be combined with oth...

er diuretics. Due to its anti-androgen effect, it can also be used to treat hirsutism, and is a common component in hormone therapy for male-to-female transgendered people. Spironolactone inhibits the effect of aldosterone by competing for intracellular aldosterone receptor in the distal tubule cells. This increases the secretion of water and sodium, while decreasing the excretion of potassium. Spironolactone has a fairly slow onset of action, taking several days to develop and similarly the effect diminishes slowly. Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Spironolactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Spironolactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone interacts with a cytoplasmic mineralocorticoid receptor to enhance the expression of the Na+, K+-ATPase and the Na+ channel involved in a Na+ K+ transport in the distal tubule . Spironolactone bind to this mineralcorticoid receptor, blocking the actions of aldosterone on gene expression. Aldosterone is a hormone; its primary function is to retain sodium and excrete potassium in the kidneys. Spironolactone is used primarily to treat low-renin hypertension, hypokalemia, and Conn's syndrome.

MICHLER'S KETONE

3Z2SN6B347

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1